1.
JTO Clin Res Rep
; 5(10): 100712, 2024 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-39309421
RESUMO
A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3-targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulted in a partial response. Bispecific T cell engagers may offer a novel treatment approach for large cell neuroendocrine carcinoma of the lung.